KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Short term Debt: 2009-2020

Historic Short term Debt for Neogenomics (NEO) over the last 8 years, with Mar 2020 value amounting to $5.0 million.

  • Neogenomics' Short term Debt fell 36.49% to $5.0 million in Q1 2020 from the same period last year, while for Mar 2020 it was $5.0 million, marking a year-over-year decrease of 36.49%. This contributed to the annual value of $5.0 million for FY2019, which is 36.49% down from last year.
  • As of Q1 2020, Neogenomics' Short term Debt stood at $5.0 million, which was down 0.00% from $5.0 million recorded in Q4 2019.
  • Neogenomics' Short term Debt's 5-year high stood at $8.8 million during Q1 2017, with a 5-year trough of $596,000 in Q1 2016.
  • Its 3-year average for Short term Debt is $6.1 million, with a median of $6.2 million in 2019.
  • In the last 5 years, Neogenomics' Short term Debt slumped by 57.72% in 2016 and then surged by 1,382.21% in 2017.
  • Neogenomics' Short term Debt (Quarterly) stood at $3.8 million in 2016, then remained steady at $3.8 million in 2017, then skyrocketed by 109.95% to $7.9 million in 2018, then crashed by 36.49% to $5.0 million in 2019, then slumped by 36.49% to $5.0 million in 2020.
  • Its Short term Debt stands at $5.0 million for Q1 2020, versus $5.0 million for Q4 2019 and $6.2 million for Q3 2019.